Literature DB >> 29307368

Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary.

Walter A Orenstein1, Lisa Cairns2, Alan Hinman3, Benjamin Nkowane4, Jean-Marc Olivé5, Arthur L Reingold6.   

Abstract

Measles, a vaccine-preventable illness, is one of the most infectious diseases known to man. In 2015, an estimated 134,200 measles deaths occurred globally. Rubella, also vaccine-preventable, is a concern because infection during pregnancy can result in congenital defects in the baby. More than 100,000 babies with congenital rubella syndrome were estimated to have been born globally in 2010. Eradication of both measles and rubella is considered to be feasible, beneficial, and more cost-effective than high-level control. All six World Health Organization (WHO) regions have measles elimination goals by 2020 and two have rubella elimination goals by that year. However, the World Health Assembly has not endorsed a global eradication goal for either disease. In 2012, the Measles and Rubella Initiative published a Global Measles and Rubella Strategic Plan, 2012-2020, referred to hereafter as the Plan, which aimed to achieve measles and rubella elimination in at least five WHO regions by end-2020 through the implementation of five core strategies, with progress evaluated against 2015 milestones. When, by end-2015, none of these milestones had been met, WHO's Strategic Advisory Group of Experts on Immunization (SAGE) recommended a mid-term review of the Plan to evaluate progress toward goals, assess the quality of strategy implementation, and formulate lessons learned. A five-member team reviewed documents and conducted interviews with stakeholders as the basis for the review's conclusions and recommendations. This team concluded that, although significant progress in measles elimination had been made, progress had slowed. It recommended that countries continue to work toward elimination goals with a focus on strengthening ongoing immunization systems. In addition, it concluded that the strategies articulated in the Plan were sound, however full implementation had been impeded by inadequate country ownership and global political will, reflected in inadequate resources. Detailed recommendations for each of the Plan's five strategies as well as the areas of polio transition, governance and resource mobilization are outlined.
Copyright © 2017 World Health Organization. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Evaluation; Immunization; Measles; Recommendations; Rubella

Mesh:

Substances:

Year:  2018        PMID: 29307368     DOI: 10.1016/j.vaccine.2017.10.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

Review 1.  Oncolytic Measles Virotherapy and Opposition to Measles Vaccination.

Authors:  Stephen J Russell; Dusica Babovic-Vuksanovic; Alice Bexon; Roberto Cattaneo; David Dingli; Angela Dispenzieri; David R Deyle; Mark J Federspiel; Adele Fielding; Eva Galanis; Martha Q Lacy; Bradley C Leibovich; Minetta C Liu; Miguel Muñoz-Alía; Tanner C Miest; Julian R Molina; Sabine Mueller; Scott H Okuno; Nandakumar Packiriswamy; Tobias Peikert; Corey Raffel; Frits Van Rhee; Guy Ungerechts; Paul R Young; Yumei Zhou; Kah-Whye Peng
Journal:  Mayo Clin Proc       Date:  2019-06-22       Impact factor: 7.616

2.  Assessment of knowledge and attitude among postnatal mothers towards childhood vaccination in Malaysia.

Authors:  Helvinder Kaur Balbir Singh; Vishal Bhagwan Badgujar; Rose Suzila Yahaya; Santibuana Abd Rahman; Farheen Mohd Sami; Sangeeta Badgujar; Subhashini Nair Govindan; Mohammed Tahir Ansari
Journal:  Hum Vaccin Immunother       Date:  2019-06-20       Impact factor: 3.452

3.  How adequate is measles surveillance in the United States? Investigations of measles-like illness, 2010-2017.

Authors:  Susannah L McKay; Jessica Leung; Paul A Gastañaduy; Janell A Routh; Rafael Harpaz
Journal:  Hum Vaccin Immunother       Date:  2020-09-03       Impact factor: 3.452

4.  Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Krista M Goergen; Diane E Grill; Min-Hsin Chen; Lijuan Hao; Joseph Icenogle; Gregory A Poland
Journal:  Vaccine       Date:  2019-11-12       Impact factor: 3.641

5.  Feasibility of measles and rubella vaccination programmes for disease elimination: a modelling study.

Authors:  Amy K Winter; Brian Lambert; Daniel Klein; Petra Klepac; Timos Papadopoulos; Shaun Truelove; Colleen Burgess; Heather Santos; Jennifer K Knapp; Susan E Reef; Lidia K Kayembe; Stephanie Shendale; Katrina Kretsinger; Justin Lessler; Emilia Vynnycky; Kevin McCarthy; Matthew Ferrari; Mark Jit
Journal:  Lancet Glob Health       Date:  2022-10       Impact factor: 38.927

6.  Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016.

Authors:  Gavin B Grant; Balcha G Masresha; William J Moss; Mick N Mulders; Paul A Rota; Saad B Omer; Abigail Shefer; Jennifer L Kriss; Matt Hanson; David N Durrheim; Robert Linkins; James L Goodson
Journal:  Vaccine       Date:  2019-03-20       Impact factor: 3.641

7.  Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey.

Authors:  Jennifer L Kriss; Gavin B Grant; William J Moss; David N Durrheim; Abigail Shefer; Paul A Rota; Saad B Omer; Balcha G Masresha; Mick N Mulders; Matt Hanson; Robert W Linkins; James L Goodson
Journal:  Vaccine       Date:  2019-03-18       Impact factor: 3.641

8.  Madagascar 2018-2019 measles outbreak response: main strategic areas.

Authors:  Vincent Dossou Sodjinou; Alfred Douba; Marcellin Mengouo Nimpa; Yolande Vuo Masembe; Mireille Randria; Charlotte Faty Ndiaye
Journal:  Pan Afr Med J       Date:  2020-09-05

9.  Descriptive epidemiology of measles cases in Bauchi State, 2013-2018.

Authors:  Polycarp Uchechukwu Ori; Ayo Adebowale; Chukwuma David Umeokonkwo; Ugochukwu Osigwe; Muhammad Shakir Balogun
Journal:  BMC Public Health       Date:  2021-07-05       Impact factor: 3.295

10.  Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients.

Authors:  Maddalena Casale; Nicoletta Di Maio; Valentina Verde; Saverio Scianguetta; Maria Grazia Di Girolamo; Rita Tomeo; Domenico Roberti; Saverio Misso; Silverio Perrotta
Journal:  Vaccines (Basel)       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.